Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries - data from the ECEE Network Group

D. Gokengin, I. Aho, F. Sarıgül Yıldırım, P. Bukovinova, E. Siwak, A. Papadopoulos, D. Sedlacek, J. Kowalska,

. 2019 ; 90 (7) : 411-415. [pub] -

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006062

OBJECTIVES: The purpose of this study was to investigate dolutegravir (DTG) use among women and exposure to DTG during pregnancy in real world in Central and Eastern Europe and neighboring countries. MATERIAL AND METHODS: Centres from 20 countries included in the Euroguidelines in Central and Eastern Europe (ECEE) Network and Finland were asked to complete an on-line questionnaire. RESULTS: Seven centres from Czech Republic, Finland, Greece, Poland, Slovakia, and Turkey provided detailed information. DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Few women had conventional risk factors. The data on folic acid usage was unknown for eight women; 14 were using and four were not using folic acid. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. CONCLUSIONS: The DTG signal report indicates the importance of safety research for drug use in pregnancy and highlights the urgent need for systematic surveillance of pregnancy outcomes and neonatal surveillance. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision.

000      
00000naa a2200000 a 4500
001      
bmc20006062
003      
CZ-PrNML
005      
20200528112609.0
007      
ta
008      
200511s2019 pl f 000 0| eng|
009      
AR
024    7_
$a 10.5603/GP.2019.0070 $2 doi
035    __
$a (PubMed)31392711
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Gokengin, Deniz $u Ege University Faculty of Medicine Department of Infectious Diseases, Izmir, Turkey. gkengin61@gmail.com.
245    10
$a Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries - data from the ECEE Network Group / $c D. Gokengin, I. Aho, F. Sarıgül Yıldırım, P. Bukovinova, E. Siwak, A. Papadopoulos, D. Sedlacek, J. Kowalska,
520    9_
$a OBJECTIVES: The purpose of this study was to investigate dolutegravir (DTG) use among women and exposure to DTG during pregnancy in real world in Central and Eastern Europe and neighboring countries. MATERIAL AND METHODS: Centres from 20 countries included in the Euroguidelines in Central and Eastern Europe (ECEE) Network and Finland were asked to complete an on-line questionnaire. RESULTS: Seven centres from Czech Republic, Finland, Greece, Poland, Slovakia, and Turkey provided detailed information. DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Few women had conventional risk factors. The data on folic acid usage was unknown for eight women; 14 were using and four were not using folic acid. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. CONCLUSIONS: The DTG signal report indicates the importance of safety research for drug use in pregnancy and highlights the urgent need for systematic surveillance of pregnancy outcomes and neonatal surveillance. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision.
650    _2
$a spotřeba léčiv $x statistika a číselné údaje $7 D004363
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyselina listová $x terapeutické užití $7 D005492
650    _2
$a HIV infekce $x farmakoterapie $7 D015658
650    _2
$a inhibitory HIV-integrasy $x terapeutické užití $7 D019428
650    _2
$a heterocyklické sloučeniny tricyklické $x terapeutické užití $7 D006575
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a těhotenství $7 D011247
650    _2
$a infekční komplikace v těhotenství $x farmakoterapie $7 D011251
650    _2
$a výsledek těhotenství $7 D011256
650    _2
$a zpožděný efekt prenatální expozice $7 D011297
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Aho, Inka $u Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Sarıgül Yıldırım, Figen $u Health Science University Antalya Education and Training Hospital, Antalya, Turkey.
700    1_
$a Bukovinova, Pavla $u Department of Infectious Diseases and Geographical Medicine UH, Bratislava, Slovakia.
700    1_
$a Siwak, Ewa $u Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland.
700    1_
$a Papadopoulos, Antonios $u University Hospital, Athens, Greece.
700    1_
$a Sedlacek, Dalibor $u HIV Centre, Department of Infectious Diseases, University Hospital, Plzen, Czech Republic.
700    1_
$a Kowalska, Justyna $u Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland. Medical University of Warsaw, Department of Adult's Infectious Diseases, Warsaw, Poland.
773    0_
$w MED00001927 $t Ginekologia polska $x 2543-6767 $g Roč. 90, č. 7 (2019), s. 411-415
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31392711 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528112607 $b ABA008
999    __
$a ok $b bmc $g 1524920 $s 1096118
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 90 $c 7 $d 411-415 $e - $i 2543-6767 $m Ginekologia polska $n Ginekol Pol $x MED00001927
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace